Lurbinectedin, also known by its brand name Zepzelca, is a medication used in the treatment of certain types of cancer. However, the provided sources do not directly mention how long lurbinectedin stays active in the environment. Therefore, I cannot provide a specific answer to your question based solely on these sources.

The first source, Drug Patent Watch, provides information about the patent status and expiration of lurbinectedin. It does not provide any information about the environmental persistence of the drug.

The second source, a study published in the National Center for Biotechnology Information (NCBI), discusses the efficacy and safety of lurbinectedin in treating small cell lung cancer. While the study provides valuable information about the drug's effectiveness and side effects, it does not address its environmental persistence.

The third source, Oncolink, is a resource for cancer treatment information. The provided link directs to a page that provides general information about lurbinectedin, including its mechanism of action, indications, and side effects. However, it does not mention anything about the drug's environmental persistence.

To determine the environmental persistence of lurbinectedin, further research is needed. This may involve consulting additional scientific studies, environmental databases, or regulatory agencies that specialize in assessing the environmental impact of pharmaceuticals.

In conclusion, based on the provided sources, there is no specific information available regarding how long lurbinectedin stays active in the environment. It is important to consult additional sources or conduct further research to obtain more accurate information on this topic.

Sources:
[1] Drug Patent Watch. (n.d.). Lurbinectedin - Trademark, owner Jazz Pharmaceuticals Inc. Retrieved from https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] National Center for Biotechnology Information. (2021). Efficacy and safety of lurbinectedin in small cell lung cancer: a systematic review and meta-analysis. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988166/
[3] Oncolink. (n.d.). Lurbinectedin (Zepzelca®). Retrieved from https://www.oncolink.org/cancer-treatment/oncolink-rx/lurbinectedin-zepzelca